Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroinflammation in Alzheimer's Disease Using [18F]NOS PET/CT
NCT04274998Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Mar 2020
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-NOS in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Uptake of [18F]NOS in the human brain at 3 years and Patterns of [18F]NOS brain uptake compared with cerebral amyloidosis and neurodegeneration at 3 years. Started Mar 2020; status: active, not recruiting.
02
Drugs
18F-NOS
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04274998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274998.